Clinical Analysis of drug inTEraction between CatecHin and Ixazomib for patieNts with multiple myeloma

Clinical Analysis of drug inTEraction between CatecHin and Ixazomib for patieNts with multiple myeloma - CATECHIN study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031235

Enrollment

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Water Green tea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >20 years old 2. Performance status 0, 1 or 2 3. Patients with relapse/refractory multiple myeloma or plasmacytoma 4. laboratory data Neutrophil >1000/microL Platelet >75000/microL T-Bil <2.25 mg/mL CCr >30 mL/min 5. Expected more than 6 months survival

Exclusion criteria

Exclusion criteria: 1. Using other anticancer drugs 2. Systemic surgery within 14 days 3. active infections 4. CNS involvement 5. uncontrolable cardiovascular disease 6. active HBV, HCV, or HIV 7. severe complications 8. difficulty in swallowing 9. mental diseases 10. allergic to study drugs 11. pregnant or Brest feeding 12. strong CYP1A2 inhibitor, strong CYP3A inhibitor, CYP3A inducer

Design outcomes

Primary

Measure	Time frame
PK parameters of Ixazomib	—

Countries

Japan

Contacts

Public ContactAkihito Kitao

Kobe University Hospital Department of Medical Oncology and Hematology

akitao@med.kobe-u.ac.jp078-382-5820

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026